From: Prognostic value of various subtypes of extracellular DNA in ovarian cancer patients
 | N | % | Total extracellular DNA ng/mL median | p-value | Extracellular nuclear DNA ge/mL median | p-value | Extracellular mitochondrial DNA ge/mL median | p-value |
---|---|---|---|---|---|---|---|---|
All patients | 67 | 100.0 | 8.3 | Â | 2266 | Â | 16,526 | NA |
Surgical Debulking | ||||||||
 Optimal | 35 | 52.2 | 8.26 | 0.35 | 1944 | 0.13 | 11,422 | 0.09 |
 Suboptimal | 32 | 47.8 | 8.94 |  | 2584 |  | 20,297 |  |
Histology | ||||||||
 Serous | 53 | 79.1 | 9 | 0.31 | 2422 | 0.63 | 16,526 | 0.70 |
 Other | 14 | 20.9 | 6.16 |  | 1919 |  | 13,117 |  |
Grade | ||||||||
 1 and 2 | 14 | 20.9 | 7.63 | 0.47 | 2083 | 0.49 | 16,470 | 0.90 |
 3 | 41 | 61.2 | 8.32 |  | 2266 |  | 15,646 |  |
 Unknown | 12 | 17.9 |  |  |  |  |  |  |
Stage | ||||||||
 1 | 12 | 17.9 | 5.3 | 0.58 | 1862 | 0.45 | 8604 | 0.16 |
 2 | 7 | 10.4 | 8.26 |  | 2422 |  | 16,526 |  |
 3 | 43 | 64.2 | 9 |  | 2455 |  | 17,575 |  |
 4 | 5 | 7.5 | 9.7 |  | 1736 |  | 16,413 |  |
Stage | ||||||||
 1 | 12 | 17.9 | 5.3 | 0.19 | 1862 | 0.18 | 8604 | 0.03 |
 2 to 4 | 55 | 82.1 | 9 |  | 2438 |  | 16,984 |  |
 |  | 0.0 |  |  |  |  |  |  |
Chemotherapy | ||||||||
 paclitaxel+carboplatin | 25 | 37.3 | 6.26 | 0.21 | 1893 | 0.19 | 14,314 | 0.76 |
 paclitaxel+carboplatin+bevacizumab | 42 | 62.7 | 9.17 |  | 2447 |  | 16,755 |  |